Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964761 | 0.91 | MEN1 (0.52) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL6212084 | 0.89 | MEN1 (0.59) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5964260 | 0.88 | CNR2 (0.60) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5964288 | 0.88 | CNR2 (0.67) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5964103 | 0.87 | GAA (0.46) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5964106 | 0.85 | MEN1 (0.41) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5963981 | 0.84 | CNR2 (0.44) | CNR2MEN1KMT2ALMNA | |
| SCHEMBL5964027 | 0.83 | MEN1 (0.43) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL6212413 | 0.83 | MEN1 (0.52) | CNR2MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5964327 | 0.82 | CNR2 (0.57) | CNR2MEN1KMT2AGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | CNR2 2/4885MEN1 4443/4885KMT2A 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.